Tumor antigens and markers in renal cell carcinoma

Urologic Clinics of North America

Volumn 30, Issue 3, 2003, Pages 455-465

  Mulders, Peter ^a   Bleumer, Ivar ^a   Oosterwijk, Egbert ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CATENIN; CADHERIN; CADHERIN 6; CYCLIN A; CYCLIN D1; CYCLINE; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; MONOCLONAL ANTIBODY G250; MUCIN 1; NERVE CELL ADHESION MOLECULE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PROTEIN RAGE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CLINICAL RESEARCH; CORRELATION ANALYSIS; CYTOGENETICS; DENDRITIC CELL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DNA FINGERPRINTING; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZATION; KIDNEY CARCINOMA; MOLECULAR MECHANICS; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SOLID TUMOR; VACCINE PRODUCTION;

EID: 0041914572     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(03)00024-7     Document Type: Review

References (52)

1. Boring CC, Squires TS, Tong T, et al. Cancer statistics. CA Cancer J Clin 1995;44:7-26.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281(17):1628-31.
3. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6(7):655-63.
4. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am 1993;20(2):247-62.
5. Medeiros LJ, Michie SA, Johnson DE, Warnke RA, Weiss LM. An immunoperoxidase study of renal cell carcinomas: correlation with nuclear grade, cell type, and histologic pattern. Hum Pathol 1988;19(8):980-7.
6. Helpap B. Grading and prognostic significance of urologic carcinomas. Urol Int 1992;48(3):245-57.
7. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163(4):1090-5.
8. Stenzl A, deKernion JB. The natural history of renal cell carcinoma. Semin Urol 1989;7:144-8.
9. Pierce WC, Belldegrun A, deKernion J, et al. Immunotherapy of patients with metastatic renal cell carcinoma (RCCa) using tumor infiltrating lymphocytes (TIL) in combination with outpatient regimen of interleukin-2 (IL2) with or without interferon-alpha (IFN-alpha): UCLA Kidney Program. Proc Am Soc Clin Oncol 1994;13:238.
10. Figlin RA, Pierce WC, deKernion J, Belldegrun A. The biology and clinical activity of CD8+ tumor infiltrating lymphocytes (CD8+ TIL) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 1993;12:288.
11. Rosenberg SA, Pachard BS, Aebersold PM, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988;318:1676-80.
12. Mulders P, Figlin R, deKernion JB, et al. Renal cell carcinoma: recent progress and future directions. Cancer Res 1997:57(22):5189-95.
13. Macdonald J. Carcinoembryonic antigen screening: pros and cons. Semin Oncol 1999;26(5):556-60.
14. Dowsett M, Cooke T, Ellis I, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000;36(2):170-6.
15. Gregorakis AK, Holmes EH, Murphy GP. Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol 1998;16(1):2-12.
16. Su SL, Boynton AL, Holmes EH, Elgamal AA, Murphy GP. Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction. Semin Surg Oncol 2000;18(1):17-28.
17. Vasavada SP, Novick AC, Williams BR. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51(6):1057-61.
18. Tomasino RM, Morello V, Tralongo V, et al. p53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization. Pathologica 1994;86(3):227-33.
19. Rioux-Leclercq N, Turlin B, Bansard J, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000;55(4):501-5.
20. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000;15;85(6):865-70.
21. Murakami Y, Kanda K, Tsuji M, et al. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 1999;83(7):743-7.
22. Nose A, Nagafuchi A, Takeichi M. Expressed recombinant cadherins mediate cell sorting in model systems. Cell 1988;54(7):993-1001.
23. Nouwen EJ, Dauwe S, van der Biest I, De Broe ME. Stage- and segment-specific expression of cell-adhesion molecules N-CAM, A-CAM, and LCAM in the kidney. Kidney Int 1993;44(1):147-58.
24. Shimazui T, Schalken JA, Giroldi LA, et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res 1996;56(18):4154-8.
25. Tanabe K, Campbell SC, Alexander JP, et al. Molecular regulation of intercellular adhesion molecule 1 (ICAM-1) expression in renal cell carcinoma. Urol Res 1997;25(4):231-8.
26. Hoffmann R, Franzke A, Buer J, et al. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer 1999;79(11-12):1742-5.
27. Aaltomaa S, Lipponen P, Ala-Opas M, et al. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer 1999;80:2001-7.
28. Lombardi D, Lacombe ML, Paggi MG. nm23: unraveling its biological function in cell differentiation. J Cell Physiol 2000;182(2):144-9.
29. Nakagawa Y, Tsumatani K, Kurumatani N, et al. Prognostic value of nm23 protein expression in renal cell carcinomas. Oncology 1998;55(4):370-6.
30. Theisinger B, Engel M, Seifert M, et al. NM23-HI and NM23-H2 gene expression in human renal tumors. Anticancer Res 1998;18(2A):1185-9.
31. Oremek GM, Teigelkamp S, Kramer W, et al. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 1999;19(4A):2599-601.
32. Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999;19(4A):2583-90.
33. Fujita K, Denda K, Yamamoto M, et al. Expression of MUC1 mucins inversely correlated with postsurgical survival of renal cell carcinoma patients. Br J Cancer 1999;80(1-2):301-8.
34. Kraus S, Abel PD, Nachtmann C, et al. MUC1 mucin and trefoil factor I protein expression in renal cell carcinoma: correlation with prognosis. Hum Pathol 2002;33(1):60-7.
35. Gilcrease MZ, Guzman-Paz M, Niehans G, et al. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 1999;86:2320-6.
36. Heider KH, Ratschek M, Zatloukal K, Adolf GR. Expression of CD44 isoforms in human renal cell carcinomas. Virchows Arch 1996;428:267-73.
37. Paradis V, Ferlicot S, Ghannam E, et al. CD44 is an independent prognostic factor in conventional renal cell carcinomas. J Urol 1999;161(6):1984-7.
38. Morell-Quadreny L, Clar-Blanch F, Fenollosa-Enterna B, et al. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in renal cell carcinoma. Anticancer Res 1998;18(1B):677-82.
39. Murphy GF, Partin AW, Maygarden SJ, Mohler JL. Nuclear shape analysis for assessment of prognosis in renal cell carcinoma. J Urol 1990;143(6):1103-7.
40. Bibbo M, Galera-Davidson H, Dytch HE, et al. Karyometry and histometry of renal cell carcinoma. Anal Quant Cytol Histol 1987;9(2):182-7.
41. Gilchrist KW, Hogan TF, Harberg J, Sonneland PR. Prognostic significance of nuclear sizing in renal cell carcinoma. Urology 1984;24(2):122-4.
42. van der Poel HG, Mulders PF, Oosterhof GO, et al. Prognostic value of karyometric and clinical characteristics in renal cell carcinoma: quantitative assessment of tumor heterogeneity. Cancer 1993;72(9):2667-74.
43. van der Poel HG, Mulders PF, Oosterhof GO, et al. Tumor heterogeneity as prognostic factor in patients with low-stage (T1-3N0M0) renal cell carcinoma. Investig Urol (Berl) 1994;5:60-5.
44. Ljungberg B, Forsslund G, Stenling R, Zetterberg A. Prognostic significance of the DNA content in renal cell carcinoma. J Urol 1986;135(2):422-6.
45. Mulder JW, Offerhaus GJ. de Feyter EP, et al. The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am J Pathol 1992;141(4):797-804.
46. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254(5038):1643-7.
47. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176(5):1453-7.
48. Gaugler B, Brouwenstijn N, Vantomme V, et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 1996;44:323-30.
49. Goydos JS, Elder E, Whiteside TL, et al. A phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996;63(1):298-304.
50. Van den Eynde BJ, Boon T. Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 1997;27(2):81-6.
51. Vissers JL, De Vries IJ, Schreurs MW, et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999;59(21):5554-9.
52. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell carcinoma: gene identification and prognostication classification. Proc Natl Acad Sci USA 2001;98:9754-9.